Nov 5, 4:19 PM ET
Protagonist Therapeutics reported third quarter 2026 financial results, highlighted by net income of $220.0 million and license and collaboration revenue of $274.4 million, driven by partner payments following FDA approval of MIMRYLO. Cash, cash equivalents, and marketable securities reached $834.6 million as of September 30, 2026. The company also announced a $300 million share repurchase program authorized in September 2026.
- Net income for the third quarter of 2026 was $220.0 million, or $3.07 per diluted share, compared to a net loss of $39.3 million, or $0.62 per diluted share, for the third quarter of 2025.
- License and collaboration revenue reached $274.4 million for the third quarter of 2026, primarily driven by $266.6 million in proportional recognition from Takeda following the FDA approval of MIMRYLO.
- Cash, cash equivalents, and marketable securities totaled $834.6 million as of September 30, 2026.
- The Board of Directors authorized a $300 million share repurchase program announced on September 8, 2026.
Read the filing on SEC.gov ↗
Aug 5, 4:11 PM ET
Protagonist Therapeutics reported net income of $162.8 million for the quarter ended June 30, 2026, compared with a net loss of $34.8 million a year earlier. Most of the quarter's $213.5 million in license and collaboration revenue came from $192.4 million recognized from the Takeda opt-out payment, so the result reflects a large one-time-style accounting benefit rather than the ongoing run rate. The company also said it expects research and development expense to rise significantly in the second half of 2026.
- Q2 2026 license and collaboration revenue was $213.5 million, versus $5.5 million in Q2 2025; $192.4 million relates to the Takeda opt-out payment.
- Q2 2026 net income was $162.8 million, or $2.29 per diluted share, versus a net loss of $34.8 million, or $0.55 per share, a year earlier.
- R&D expense was $42.1 million in Q2 2026, up from $37.0 million, and the company expects R&D expense to increase significantly in the second half of 2026.
- Cash, cash equivalents and marketable securities were $849.5 million at June 30, 2026, up from $646.0 million at December 31, 2025; rusfertide has an FDA PDUFA goal date in August 2026.
Read the filing on SEC.gov ↗
Jun 18, 4:30 PM ET
At its annual meeting, Protagonist Therapeutics stockholders approved the company's 2026 Equity Incentive Plan, which replaces the 2016 plan and adds 650,000 new shares for future awards. Stockholders also re-elected two Class I directors and approved the other proposals, including a non-binding say-on-pay vote and the ratification of Ernst & Young LLP as auditor.
- 2026 Equity Incentive Plan approved, adding 650,000 new shares plus returned shares from the 2016 plan
- Dinesh V. Patel, Ph.D., received 48,714,702 votes for and Lewis T. "Rusty" Williams, M.D., Ph.D., received 45,371,193 votes for
- Non-binding say-on-pay proposal approved with 53,412,559 votes for and 3,164,702 against
- Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2026
Read the filing on SEC.gov ↗
May 5, 4:08 PM ET
Protagonist reported first-quarter 2026 results, with net income of $3.8 million ($0.05 per diluted share) compared with a net loss of $11.7 million ($0.19 per share) a year earlier. Revenue rose to $56.4 million from $28.3 million, mainly due to a $50.0 million milestone from Johnson & Johnson after the FDA approved ICOTYDE, so shareholders should note that the profit depends heavily on this one-time payment while R&D spending also increased.
- Net income of $3.8 million, or $0.05 per diluted share, versus a net loss of $11.7 million, or $0.19 per share, in Q1 2025
- License and collaboration revenue of $56.4 million, including a $50.0 million milestone from Johnson & Johnson tied to FDA approval of ICOTYDE in March 2026
- R&D expense rose to $46.7 million from $35.9 million, driven mainly by the PN-881 Phase 1 study and discovery research
- Cash, cash equivalents and marketable securities were $620.3 million at March 31, 2026, down from $646.0 million at December 31, 2025
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.